Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

GlobeNewswire January 26, 2022

Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities

GlobeNewswire January 26, 2022

Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference

GlobeNewswire January 20, 2022

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

Accesswire January 12, 2022

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

GlobeNewswire January 5, 2022

Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer

GlobeNewswire December 23, 2021

Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates

GlobeNewswire November 4, 2021

Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 8, 2021

Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates

GlobeNewswire August 4, 2021

Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing

GlobeNewswire July 29, 2021

Aeterna Zentaris (TSX:AEZS) engages Dr. Michael Levy to support the development of Autoimmune and Inflammatory CNS Disorders Programs

John Ballem  June 7, 2021

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

GlobeNewswire June 7, 2021

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

GlobeNewswire June 3, 2021

Betting Big On What Could Be The Next Great Biotech Boom

Press Releases May 18, 2021

Aeterna Zentaris (TSX:AEZS) announces start of preclinical development of Macimorelin

Brieanna McCutcheon  May 17, 2021

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's Disease)

GlobeNewswire May 17, 2021

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

GlobeNewswire May 13, 2021

Aeterna Zentaris to Present at the Q2 Virtual Investor Summit

GlobeNewswire May 10, 2021

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

GlobeNewswire May 6, 2021

Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders

GlobeNewswire May 5, 2021